



EpiCARE

Research calls

Dear all,

We are glad to share the **current research calls**, carefully selected for you by the EpiCARE Research Council.

You can read more information about the new funding opportunities on the [research council](#) webpage.

1. TBC1D24 Foundation funding opportunity

Budget: up to \$10,000

Deadline: March 31, 2022

Focus Areas: TBC1D24 gene mutation variants, related seizure research, related symptom research; other topics welcome.

[More information](#)

The TBC1D24 Foundation, with funding from generous donors, is accepting applications for a total of USD \$10,000.00 for scientific and/or clinical research studies related to natural history, treatment and research. Consideration will be given to applicants in the field of neurology, genetics and behavior. Interest and efforts in furthering understanding of the TBC1D24 gene mutation are appreciated and the impact it will have on the families.

The TBC1D24 Foundation 2022 Grant is being established to encourage meritorious scientific and clinical studies designed to improve the diagnosis or therapy of individuals with a TBC1D24 gene mutation. Proposals that focus on defining the natural history, early detection and diagnosis, or novel treatment strategies will be given priority.

2. 2022 Early-stage investigator grant

CHD2-related disorders

LOI Deadline: 4/15/22

Application Dates:

Send LOI via email to info@curechd2.org no later than April 15, 2022

LOIs will be reviewed and invitations for full grant proposals will be sent by May 15, 2022

Full Grant Proposals are due to info@curechd2.org by July 11, 2022

Award Announcement will be made by no later than August 15, 2022

Research Project Start Date - immediately upon CCC's receipt of a fully executed contract

Budget: \$30,000

Through our Early-Stage Investigator Grant Program, CCC hopes to accelerate the development of therapeutic treatments and disease-modifying advancements for those living with CHD2-related disorders. This grant program is designed to facilitate preliminary investigations that will potentially lay the groundwork for subsequent grants from the government, industry, or other funding sources, including Coalition to Cure CHD2.

CCC is interested in supporting research that advances the understanding of the cellular, molecular, genetic, and systems-level mechanisms of CHD2-related disorders. However, priority will be given to innovative projects which could potentially lead to therapeutic treatments or a cure for those with CHD2-related disorders.

[More information](#)

3. Implementing digital services to empower neuroscience research for health and brain inspired technology via EBRAINS

HORIZON-INFRA-2022-SERV-01-01

Deadline model: single-stage

Deadline: 21 September 2022 17:00:00 Brussels time

Budget : €38 000 000

Expected Outcome

integrated multi-disciplinary collaborative tools and services widely serving the European neuroscientific community, providing them with FAIR data indexing and archival, multilevel data mining and modelling/simulation of brain functions, and empowering workflows for reproducible research;

a rich collection of multilevel human brain models, atlases and workflows, directly supporting the research and development for personalised brain medical treatments e.g. target binding drugs, precise neuro-stimulation positioning and guided surgery, regarding brain diseases such as epilepsy, Parkinson, consciousness disorders, or rare or multi-factor diseases;

a comprehensive set of cognitive brain model scaffolds and associated modular / large-size neuromorphic and neurorobotic facilities for assisting the design and validation of applicative cognitive technologies benefitting from neurosciences latest knowledge, as enablers for autonomous and adaptive robotics approaches that use fast sensory processing and decision-making capabilities;

supplementary population of EBRAINS facilities with multidisciplinary services/applications that answer well-identified new neuroscience related S&T needs, in correlation with national and European research priorities for neuroscience, brain medicine and cognitive-technologies;

integration of EBRAINS with EOSC and linkage with common European data spaces in the life science and health sector;

better-aligned national investments in neuroscience across Europe, building on the Member States' and Associated Countries' specialised competence centres, which in turn will help creating additional synergies and enabling further research activities around the EBRAINS services.

[More information](#)

4. EIC Pathfinder Open 2022

Budget: €183 000 000

Deadline model: single-stage

Deadline: 04 May 2022 17:00:00 Brussels time

Scope

You should apply to this call if you are looking for support from EIC Pathfinder Open to realise an ambitious vision for radically new technology, with potential to create new markets and/or to address global challenges. EIC Pathfinder Open supports early stage

development of such future technologies (e.g. various activities at low Technology Readiness Levels 1-4), based on high-risk/high-gain science-towards-technology breakthrough research (including 'deep-tech'). This research must provide the foundations of the technology you are envisioning.

EIC Pathfinder Open may support your work, especially if it is highly risky: you may set out to try things that will not work; you may be faced with questions that nobody knows the answer to yet; you may realise that there are many aspects of the problem that you do not master. On the contrary, if the path you want to follow is incremental by nature or known, EIC Pathfinder Open will not support you.

Before applying you should verify that your proposal meets all the following essential characteristics ('Gatekeepers'):

Convincing long-term vision of a radically new technology that has the potential to have a transformative positive effect to our economy and society.

Concrete, novel and ambitious science-towards-technology breakthrough, providing advancement towards the envisioned technology.

High-risk/high-gain research approach and methodology, with concrete and plausible objectives.

[More information](#)

5. EIC Transition Challenge: RNA-based therapies and diagnostics for complex or rare genetic diseases

HORIZON-EIC-2022-TRANSITIONCHALLENGES-03

Budget: €131 360 126 (Grants of up to EUR 2.5million)

Deadline model: multiple cut-off

Deadline dates: 04 May 2022 17:00:00 Brussels time / 28 September 2022 17:00:00 Brussels time

[More information](#)

Is intended to meet the following specific objectives:

Advance, beyond the state-of-the-art, RNA delivery methods, including robust mRNA formulations, that would enable effective and safe delivery of mRNA into the cells;

Design, develop and preclinical validate of novel miRNAs (miRNA lncRNA, tRNA or siRNA-based) therapies for complex or rare genetic diseases;

Develop and validate novel RNA-based diagnostics and RNA-based predictive biomarkers that would allow for early and more accurate diagnosis and for favourable or non- post-treatment prognosis, respectively.

The starting point in the project should be a preliminary technology or protocol of an RNA-based therapy for complex or rare genetic diseases with unmet medical needs that demonstrates, in a lab or preclinical context, the essential features that underpin the disruptive nature of the innovation. The endpoint in the project should be a completely functional version of the technology suitable for clinical validation, supported by a sound and implementable commercialisation/exploitation strategy.

Proposals are expected to contribute to at least one of the following outcomes:

novel technological solutions leading to more effective and safer RNA delivery methods applicable to a wide range of non-infectious diseases;

utilisation of RNAs to molecularly classify sub-types of different solid tumours that would allow for stratification of patients leading to more effective and precise treatments in complex diseases with high-unmet medical needs;

novel and sound ideas for the development and validation of RNA-based therapeutic platforms and drugs;

all the projects should lead to a sufficiently mature and sound data for being ready to be up taken to the (pre-) clinical trials.

6. MSCA Doctoral Networks 2022

Budget: €427 276 125 (Per project: 36 months)
Deadline model: single-stage
Deadline: 15 November 2022 17:00:00 Brussels time

[More information](#)

Scope

The Doctoral Networks aim to train a new generation of creative entrepreneurial and innovative early-stage researchers, able to face current and future challenges and to convert knowledge and ideas into products and services for economic and social benefit.

For supported doctoral candidates

New research and transferable skills and competences, leading to improved employability and career prospects within and outside academia;

New knowledge allowing the conversion of ideas into products and services, where relevant;

Enhanced networking and communication capacities with scientific peers, as well as with the general public that will increase and broaden the research and innovation impact.

For participating organizations:

Improved quality, relevance and sustainability of doctoral training programmes and supervision arrangements;

Enhanced cooperation and transfer of knowledge between sectors and disciplines;

Increased integration of training and research activities between participating organisations;

Boosted R&I capacity;

Increased internationalisation and attractiveness;

Regular feedback of research results into teaching and education at participating organisations.

7. MSCA Postdoctoral Networks 2022

Deadline model: single-stage

Deadline date: 14 September 2022 17:00:00 Brussels time

Budget:

For Global Fellowships: €38 550 000 (Per project: duration from 24 to 36 months)

For European Fellowships: €218 450 000 (Per project: duration from 12 to 24 months)

Scope

Fellowships will be provided to excellent researchers, undertaking international mobility either to or between EU Member States or Horizon Europe Associated Countries, as well as to non-associated Third Countries. Applications will be made jointly by the researcher and a beneficiary in the academic or non-academic sector.

Postdoctoral Fellowships either can take place in Europe (i.e. in an EU Member State or a Horizon Europe Associated Country) or in a Third Country not associated to Horizon Europe:

European Postdoctoral Fellowships are open to researchers of any nationality who wish to engage in R&I projects by either coming to Europe from any country in the world or moving within Europe. The standard duration of these fellowships must be between 12 and 24 months.

Global Postdoctoral Fellowships are open to European nationals or long-term residents^[1] who wish to engage in R&I projects with organisations outside EU Member States and Horizon Europe Associated Countries. These fellowships require an outgoing phase of minimum 12 and maximum 24 months in a non-associated Third Country, and a mandatory 12-month return phase to a host organisation based in an EU Member State or a Horizon Europe Associated Country.

[More information](#)

8. New methods for the effective use of real-world data and/or synthetic data in regulatory decision-making and/or in health technology

assessment

HORIZON-HLTH-2022-TOOL-11-02

Deadline model: single-stage

Deadline: 21 April 2022 17:00:00 Brussels time

Budget : €35 000 000 (around EUR 7.00 million per project)

[More information](#)

Scope

With the emerging use of real-world data (RWD) and synthetic data by the pharmaceutical industry and medical devices industry, regulators and HTA bodies need to perform targeted validation of claims through independent analysis. The principal aim of this topic is to address the data needs of health regulatory bodies and HTA bodies across the EU, as outlined in the recently published “HMA-EMA Joint Big Data Taskforce Phase II report: ‘Evolving Data-Driven Regulation’”[2] and its associated DARWIN (Data Analysis and Real World Interrogation Network) project[3].

To harness the potential of RWD and synthetic data from digital twins and advanced analytical models, and make them actionable for health regulatory decision-making and for health technology assessment, targeted research is needed on the evidentiary value of these data for a number of relevant use cases. In addition, methods need to be developed to increase the usability of such data by different stakeholder groups. Doing so will contribute to the European Health Data Space and maximise the positive impact of DARWIN in driving up the quality of evidence and decisions on the development and use of medicines and digital health innovations.

Access to and analysis of RWD and synthetic data can inform regulatory decision-making throughout the product lifecycle, namely: 1) support product development (e.g. scientific advice, PRIME[4],); 2) support authorisation of new medicines and digital health innovations; and 3) monitor the performance of medicines and digital health innovations on the market (effectiveness and safety). Eventually, this will put in place methods and processes that will enable continuous learning from pre-authorisation procedures and authorisation applications on the use of RWD and/or synthetic data.

9. ERC ADVANCED GRANTS

Deadline model: single-stage

Deadline: 28 April 2022 17:00:00 Brussels time

[More information](#)

Budget

Advanced Grants may be awarded up to a maximum of EUR 2 500 000 for a period of 5 years (the maximum award is reduced pro rata temporis for projects of a shorter duration).

However, up to an additional EUR 1 000 000 can be requested in the proposal to cover (a) eligible "start-up" costs for Principal Investigators moving to the EU or an Associated Country from elsewhere as a consequence of receiving the ERC grant and/or (b) the purchase of major equipment and/or (c) access to large facilities and/or (d) other major experimental and field work costs, excluding personnel costs. (As any additional funding is to cover major one-off costs it is not subject to pro-rata temporis reduction for projects of shorter duration. All funding requested is assessed during evaluation).

Objectives

ERC Advanced Grants are designed to support excellent Principal Investigators at the career stage at which they are already established research leaders with a recognised track record of research achievements. Principal Investigators must demonstrate the ground-breaking nature, ambition and feasibility of their scientific proposal.

10. Open Access Publication Support Program - Dravet Syndrom

Deadline: December 31, 2022

Budget: €2 000

[More information](#)

The Dravet Syndrome Foundation Spain (FSD) Open-Access Support Program is an ongoing call for proposals, and it joins recent research initiatives initiated by FSD, such as the Call for Innovative Research Projects in Advanced Therapies for Dravet Syndrome or the Program for the development of new scientific tools initiated last February 1st together with Tel Aviv University.

This is an ongoing call only limited by FSD's budget. Authors can apply for a grant of up to EUR 2,000 (approximately \$2400 USD) to cover the open-access publishing fees required for the publication in international scientific journals of a manuscript resulting from high quality research on Dravet syndrome.

11. Innovative Health Initiative (IHI)

The [Innovative Health Initiative](#) (IHI), a European Union public-private partnership funding health research and innovation, has published draft information on upcoming funding opportunities in 2022 in order to give potential applicants additional time to find or build a consortium and prepare a strong proposal.

The first call for proposals will be launched in the first half of 2022. The following draft themes could be included in the future calls:

Single stage calls

- Innovative patient-facing care pathways for patients with neurodegenerative diseases and comorbidities
- Next generation imaging and image-guided diagnosis and therapy for cancer
- Precision oncology: Innovative patient-centric, multi-modal therapies against cancer
- Access and integration of heterogeneous health data for improved health care in diseases areas of high unmet public health need.

Two stage calls

- New tools for prediction, prevention and monitoring of cardio-metabolic diseases including secondary manifestations to enable timely intervention
 - Strengthening EU clinical development excellence and innovation attractiveness: Harmonised methodology to promote the uptake of early feasibility studies (EFS)
- Please check the [IHI website](#) and social media for regular updates related to the upcoming calls.

[More information on these calls](#)



European
Reference
Networks

Co-funded by the European Union



Our mailing address is:

Department of Paediatric Clinical Epileptology, Sleep Disorders and Functional Neurology
ERN EpiCARE c/o Pr Arzimanoglou
Hôpital Femme Mère Enfant (HFME)
59 Boulevard Pinel
69677 Bron, FRANCE

[Unsubscribe](#)

© 2021 EpiCARE All rights reserved.

You are receiving this email as you may work at one of the EpiCARE centres, or you are taking part in one or more of EpiCARE expert groups, or you may have attended one of our webinars.

[Having Trouble Viewing This Email? Open this newsletter in your browser](#)

© 2021 Hospices Civils de Lyon (ERN EpiCARE)